stockrow
Friday 6 November 2026
Export ALZN’s income statement to Excel — free account
Alzamend Neuro, Inc.
ALZN Healthcare Biotechnology
- EPS
- +46.9%
- Free cash flow
- +51.8%
Quarter to July 2026, against a year earlier
1.43
0.12
−7.74%
Follow ALZN
Alert me
Alzamend Neuro, Inc. (ALZN) P/E ratio
Alzamend Neuro, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| XTLB XTL Biopharmaceuticals Ltd. compare | n/m |
| MTVA MetaVia Inc. compare | n/m |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | n/m |
| TCRT Alaunos Therapeutics, Inc. compare | n/m |
| SNGX Soligenix Inc. compare | n/m |
| ALZN Alzamend Neuro, Inc. | n/m |
| TPST Tempest Therapeutics, Inc. compare | n/m |
| VTGN VistaGen Therapeutics, Inc. compare | n/m |
| TOVX Theriva Biologics, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)